CanSense, a Swansea, UK-based developer of blood test to detect early-stage bowel cancer, raised £1.5M in funding.
The round was led by Mercia, the Development Bank of Wales, and Nonacus.
The company intends to use the funds to further develop the product and carry out clinical trials in order to meet regulatory requirements and bring it to market.
Led by CEO Adam Bryant, CanSense provides a test which combines laser spectroscopy with artificial intelligence that is faster, less expensive and less invasive than a colonoscopy procedure and more acceptable for patients than a faecal blood detection kit. It could help detect bowel cancer at an early stage when it is much easier to treat and the chance of survival is much higher.
CanSense’s blood test is based on research by Professor Peter Dunstan, Professor Dean Harris and Dr Cerys Jenkins at Swansea University which was part funded by Cancer Research Wales. They joined forces with Dr Adam Bryant, an entrepreneur and former investment banker with a PhD in physics, to set up CanSense in 2019.
FinSMEs
08/03/2023